Richard B. Lipton, MD

home / authors / richard-b-lipton-md

Articles

State of Migraine Care and Therapeutics: Richard B. Lipton, MD

July 13th 2022

The director of the Montefiore Headache Center provided an overview of the recent advances in migraine medications and how it has translated to improved care. [WATCH TIME: 2 minutes]

Advantages in Adding Intranasal Zavagepant to the Migraine Treatment Landscape: Richard B. Lipton, MD

Richard B. Lipton, MD

July 11th 2022

The director of the Montefiore Headache Center provided commentary on how analyses presented at AHS 2022 further support the benefits intranasal zavagepant bring to the migraine treatment landscape. [WATCH TIME: 5 minutes]

Efficacy, Safety of Rimegepant When Used Both as Preventively and As-Need: Richard B. Lipton, MD

Richard B. Lipton, MD

July 10th 2022

The director of the Montefiore Headache Center provided insight on an open-label study presented at AHS 2022 that highlighted rimegepant’s (Nurtec ODT; Biohaven) impact both as a preventative and acute medication. [WATCH TIME: 5 minutes]

Understanding the Impact of MiCOAS Qualitative Study: Richard B. Lipton, MD

Richard B. Lipton, MD

July 8th 2022

The director of the Montefiore Headache Center discussed the intuitiveness and advantages the Migraine Clinical Outcome Assessment System, or MiCOAS, grant provides to clinical trials and patients with migraine. [WATCH TIME: 5 minutes]

AHS 2021 Takeaways and the State of Migraine Research: Richard B. Lipton, MD

Richard B. Lipton, MD

June 29th 2021

The director of the Montefiore Headache Center discussed the momentum within the migraine research community as well as some of the more notable presentations from AHS 2021.

Exploring New Therapy Combinations to Treat Migraine: Richard B. Lipton, MD

Richard B. Lipton, MD

June 15th 2021

The director of the Montefiore Headache Center discussed future aspirations and potential combinations that should be researched to treat patients with migraine.

Concomitant Use of Ubrogepant With CGRP Monoclonal Antibodies: Richard B. Lipton, MD

Richard B. Lipton, MD

June 10th 2021

The director for the Montefiore Headache Center discussed the COURAGE study and how to effectively use a layered treatment approach with ubrogepant and CGRP monoclonal antibodies.

Advantages of Migraine Buddy App: Richard B. Lipton, MD

Richard B. Lipton, MD

June 8th 2021

The director of the Montefiore Headache Center detailed the ways the Migraine Buddy app can help simplify conducting migraine clinical trials while expanding the reach of patients.

Impact of Alleviating Migraine: Richard B. Lipton, MD

Richard B. Lipton, MD

March 25th 2021

The director of the Montefiore Headache Center discussed recent advances in treating migraine both acutely and preventively.

Further Research on Rimegepant for Migraine Prevention: Richard B. Lipton, MD

Richard B. Lipton, MD

March 14th 2021

The director of the Montefiore Headache Center discussed the research he would like to see into the treatment, including the potential of combination approaches.

Rimegepant vs. Monoclonal Antibodies for Migraine Prevention: Richard B. Lipton, MD

Richard B. Lipton, MD

February 22nd 2021

The director of the Montefiore Headache Center discussed how rimegepant has certain benefits over monoclonal antibodies, such as a much shorter half-life.

Cutting Down Monthly Headache Days in Migraine: Richard B. Lipton, MD

Richard B. Lipton, MD

February 18th 2021

The director of the Montefiore Headache Center discussed the impact of halving headache days for patients with migraine.

Clinically Meaningful Migraine Prevention: Richard B. Lipton, MD

Richard B. Lipton, MD

February 11th 2021

The director of the Montefiore Headache Center discussed how rimegepant was observed to produce clinically meaningful improvements in migraine prevention.

Preventing While Treating Acute Migraines: Richard B. Lipton, MD

Richard B. Lipton, MD

January 29th 2021

The director of the Montefiore Headache Center discussed his hopes that rimegepant will be approved as a preventive treatment of migraine.

Richard B. Lipton, MD: Achieving Simultaneous Acute and Preventive Migraine Treatment

Richard B. Lipton, MD

January 18th 2021

The director of the Montefiore Headache Center discussed how his team’s findings can change the way physicians think about treating migraine.

Richard B. Lipton, MD: CGRP Receptor-Targeting in the Prevention of Migraine

Richard B. Lipton, MD

January 13th 2021

The director of the Montefiore Headache Center discussed the current landscape of migraine treatments.